<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231011059689N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-16</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>comparison of the effect of the three methods of hemofiltration during CABG on kidney function</public_title>
      <acronym></acronym>
      <scientific_title>comparison of the effect of modified and conventional hemofiltration and combination of the two methods during cardiopulmonary bypass during coronary artery bypass graft surgery (CABG) on kidney function</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73113</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: Eligible patients are assigned to three intervention groups using block randomization method. In this way, according to the three groups of intervention and the type of intervention, 120 blocks of 6 that are a combination of interventions will be formed. And then among these blocks, 810 blocks will be randomly selected and based on that, the patients in each block will be assigned to the desired intervention group, Blinding description: This study will be conducted in a double-blind manner, so that the patient and the person analyzing the data will not know about the intervention groups.there will be no possibility of blinding for the doctor and nurse.</study_design>
      <phase>N/A</phase>
      <hc_freetext>: Comparing the effect of hemofiltration with modified and conventional methods during heart and lung pumping on kidney function (24-hour urine volume, glomerular filtration rate and CrCl after surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: the group in which hemofiltration is performed by the common method (CUF/Conventional). In this group, during heart and lung bypass, the blood is transferred to the hemofilter through the high-pressure part of cardioplegia and passes through the fibers and removes excess fluids and inflammatory factors. Intervention 2: Intervention group: Intervention group: the group in which hemofiltration is performed by a new or advanced method (MUF/modified). In this method, after completing the cardiopulmonary bypass, the blood is transferred to the cardioplegia head pump through the venous line and transferred to the hemofilter through the power of this pump, and after removing excess fluids and inflammatory factors, it is returned to the patient's arterial system through the arterial line. Intervention 3: Intervention group: A group in which both MUF (new) and CUF (common) methods are performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is A decision will be made depending on the opinion of the esteemed statistics expert and the esteemed tutor.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Mehran Shahzamani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>the third moshtaq st. , Salman Farsi st. , Chamran center of cardiovascular surgery , Isfahan , Iran</address>
        <city>اصفهان</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8179689367</zip>
        <telephone>0098 31 2600961</telephone>
        <email>drshahzamani@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Mehran Shahzamani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>the third moshtaq st. , Salman Farsi st. , Chamran center of cardiovascular surgery , Isfahan , Iran</address>
        <city>اصفهان</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8179689367</zip>
        <telephone>0098 31 2600961</telephone>
        <email>drshahzamani@yahoo.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients between 35 and 60 years old
consciously able to sign a consent letter for participating in this research
a candidate for coronary artery bypass graft.
recognized by a left ventricle ejection fraction of more than 45%
recognized by a gloumeral filtarion rate between 70 and 120</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients recognized by a left ventricle ejection fraction of less than 45%
recent MI
a gloumeral filtration rate of less than 70 mili litrs per minute
kidney failure
serum creatinine of more than 1.3 miligrams per decilitr
emergency surgery
a history of diabetic nephropathy
a conjoint valve surgery
proteinuria</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: the group in which hemofiltration is performed by the common method (CUF/Conventional). In this group, during heart and lung bypass, the blood is transferred to the hemofilter through the high-pressure part of cardioplegia and passes through the fibers and removes excess fluids and inflammatory factors.</i_keyword>
      <i_keyword>Intervention group: Intervention group: the group in which hemofiltration is performed by a new or advanced method (MUF/modified). In this method, after completing the cardiopulmonary bypass, the blood is transferred to the cardioplegia head pump through the venous line and transferred to the hemofilter through the power of this pump, and after removing excess fluids and inflammatory factors, it is returned to the patient's arterial system through the arterial line.</i_keyword>
      <i_keyword>Intervention group: A group in which both MUF (new) and CUF (common) methods are performed</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum creatinine. Timepoint: before coronary artery bupass graft surgery - 24 hours after CABG - 72 hours after CABG. Method of measurement: Collection of venous blood sample and measurement of serum creatinine in clinical laboratory.</prim_outcome>
      <prim_outcome>Creatinine clearance. Timepoint: before coronary artery bupass graft surgery - 24 hours after CABG - 72 hours after CABG. Method of measurement: calculating the amount using the quantity of serum creatinine and the formula :  CrCl(ml⁄min) = ((140-age)*lean body weight(kg))/(serum creatinine(mg/dl)*72) * (0.85 if female).</prim_outcome>
      <prim_outcome>Gloumeral filtration rate. Timepoint: before coronary artery bupass graft surgery - 24 hours after CABG - 72 hours after CABG. Method of measurement: Calculation of the amount based on the amount of serum creatinine and a defined constant with the help of the Cockcroft-Gallt formula : eGFR=((140-age)*weight*constant)/(serum creatinine)    constant = 1.23 for men and 1.04 for women.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-11</approval_date>
        <contact_name>Ethics committee of isfahan university of medical science</contact_name>
        <contact_address>No 412, fifth alley, Mehryar st, Janbazan st Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
